Table 1 Clinicopathological Characteristics of the Studied Patients
Variables | N (%) | |
|---|---|---|
Age | ≤ 60 | 9 (30.0%) |
> 60 | 21 (70.0%) | |
Gender | Female | 8 (26.7%) |
Male | 22 (73.3%) | |
Smoking history | Former smoker current | 20 (66.7%) |
Smoker | 4 (13.3%) | |
Non-smoker | 6(20%) | |
Specific type of the NSCLC | Adenocarcinoma | 15 (50%) |
Squamous | 5 (16.7%) | |
Large cell | 2 (6.7%) | |
NOS | 8 (26.6%) | |
Tumor grade | Moderate | 12 (40%) |
Undifferentiated | 8 (26.7%) | |
Undetermined tumor grade | 10 (33.3%) | |
T stage | ||
T1 | 2 (6.7%) | |
T2 | 9 (30%) | |
T3 | 4 (13%) | |
T4 | 15 (50%) | |
N stage | ||
N0 | 4 (13.3%) | |
N1 | 5 (16.7%) | |
N2 | 12 (40%) | |
N3 | 9 (30%) | |
M stage | ||
M0 | 14 (46.7%) | |
M1a | 7 (23.3%) | |
M1b | 2 (6.7%) | |
M1c | 7 (23.3%) | |
Clinical Stage | Stage I/II (32.5%) Stage III (26.7%) Stage IV (40.8%) | |
Chemotherapy alone | 26 (83.3%) | |
Surgical resection with chemotherapy | 4 (16.7%) | |
Mean ± SD | M (min–max) | |
|---|---|---|
Overall survival (months) | 17.32 ± 10.73 | 14.5(4–36) |
SUVmax | 11.19 ± 6.60 | 11.30 (1.20–31.80) |
SUVmean | 6.8 ± 3.89 | 6.6 (0.7–18.5) |
Primary MTV | 41.32 ± 39.90 | 23.65(3.7–152.7) |
Primary TLG | 306.07 ± 316.35 | 190 (1.2–1011) |
WB MTV | 185.45 ± 289.28 | 141.99 (3.09–1513.18) |
WB TLG | 1184.47 ± 205.01 | 800.97 (5.75–9671.85) |